Results of the present study showed lower levels of pretreatment CYFRA21-1, NSE, and CEA of the eligible patients versus healthy individuals, indicating that the diagnostic value of CYFRA21-1, NSE, and CEA in NSCLC. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.